Recommendations for management of dyslipidemia in 2014;Prise en charge des dyslipidémies en 2014

Revue Medicale Suisse

Volumn 10, Issue 420, 2014, Pages 518-524

  Moser, M ^a   Gencer, B ^b   Rodondi, N ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Service de Cardiologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; HIGH RISK POPULATION; HUMAN; LIFESTYLE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROCAM SCORE; RISK ASSESSMENT; SECONDARY PREVENTION; SWITZERLAND;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC;

EID: 84898607829     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816.
2. * Nanchen D, Chiolero A, Marques Vidal PM, et al. Prescription de statines en prévention primaire: quel score de risque cardiovasculaire faut-il utiliser en Suisse? Rev Med Suisse 2010;6:488-93.
3. Rodondi N, Gencer B, Collet TH, Battegay E. Quels niveaux de cholestérol devrait-on traiter en Suisse? Forum Med Suisse 2011;11:467-72.
4. Cornuz J, Auer R, Senn N, Guessous I, Rodondi N. Prévention primaire et dépistage chez l'adulte: mise à jour 2010. Rev Med Suisse 2010;6:2276-85.
5. * Brun N, Rodondi N. Dépistage et prise en charge des dyslipidémies familiales: point de vue du pédiatre et de l'interniste généraliste. Rev Med Suisse 2012;8:494-500.
6. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidemias. Eur Heart J 2011;32:1769-818.
7. * Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013; epub ahead of print.
8. ** Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC Guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013; epub ahead of print.
9. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-32.
10. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002;360:1623-30. (Pubitemid 35379733)
11. ** Doser Joz-Roland N, Büla C, Rodondi N. Fautil traiter les dyslipidémies chez les personnes âgées et très âgées? Rev Med Suisse 2009;5:2211-8.
12. ** Brosteaux C, Ruiz J, Buclin T, Kuntzer T, Rodondi N. Statines et effets indésirables musculaires. Rev Med Suisse 2010;6:510-7.